Letters

Aspirin for everyone over 50?: Authors' reply

BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7509.161-c (Published 14 July 2005) Cite this as: BMJ 2005;331:161
  1. Peter Elwood, chairman (pelwood@doctors.org.uk),
  2. Gareth Morgan, secretary,
  3. Ginevra Brown, statistician,
  4. Janet Pickering, statistician
  1. Welsh Aspirin Group, Department of Epidemiology, Statistics and Public Health, Cardiff University, Llandough Hospital, Penarth CF64 2XW
  2. Welsh Aspirin Group, Department of Epidemiology, Statistics and Public Health, Cardiff University, Llandough Hospital, Penarth CF64 2XW

    EDITOR—The case for the wider use of aspirin in vascular prophylaxis arises from the belief that subjects should be empowered to make their own decision about protecting their own health. This will be achieved only if information on the risks and benefits of preventive measures, including low dose aspirin, is widely available.

    Granted, the numerical risk-harm balance of aspirin in trials based …

    View Full Text

    Sign in

    Log in through your institution

    Subscribe